Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

Nanostring Technologies announces nationwide availability of Prosigna Breast Cancer Assay in 2014

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced nationwide availability of the Prosigna™ Breast Cancer Prognostic Gene Signature Assay beginning in the first quarter of 2014.

From NanoString Technologies 11 Dec 2013

Genetic deficiency in males can trigger hepatocellular carcinoma, type 2 diabetes

Michigan State University researchers have uncovered a genetic deficiency in males that can trigger the development of one of the most common types of liver cancer and forms of diabetes.

9 Dec 2013

Study helps explain why survival gap persists for African-Americans with head and neck cancer

A team of scientists at Johns Hopkins and in Texas has identified a handful of genetic mutations in black Americans, in addition to some chemical alterations affecting gene activity, which may help explain why the death rate among African-Americans from the most common form of head and neck cancer continues to hover some 18 percent higher above the death rate of whites with the same cancer.

9 Dec 2013

Increased levels of protein HSET linked with worse breast cancer outcomes in African-Americans

Among African-American women with breast cancer, increased levels of the protein HSET were associated with worse breast cancer outcomes, according to results presented here at the Sixth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Dec. 6-9.

9 Dec 2013

Study: Ethnic groups with high prevalence of diabetes have high hepatocellular carcinoma rates

Diabetes was associated with an increased risk for developing a type of liver cancer called hepatocellular carcinoma, and this association was highest for Latinos, followed by Hawaiians, African-Americans, and Japanese-Americans, according to results presented here at the Sixth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Dec. 6-9.

9 Dec 2013

MassBiologics gets FDA orphan drug designation for MBL-HCV1 antibody

MassBiologics of the University of Massachusetts Medical School has received an orphan drug designation from the U.S. Food and Drug Administration for MBL-HCV1, a monoclonal antibody developed to prevent hepatitis C virus recurrence in patients receiving a liver transplant.

5 Dec 2013

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis will present updates on its broad cancer portfolio with more than 240 abstracts at the upcoming American Society of Hematology (ASH) annual meeting and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

4 Dec 2013

LabCorp's HCV GenoSure NS3/4 test now available for Q80K polymorphism screening

Laboratory Corporation of America Holdings announced today the immediate availability of an enhanced version of its HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism. Q80K is a naturally occurring polymorphism that develops in certain strains of HCV, making the virus less susceptible to Janssen Therapeutics' OLYSIO (simeprevir), which was recently approved by the U.S. Food and Drug Administration for the treatment of certain adult patients diagnosed with genotype 1chronic hepatitis C.

3 Dec 2013

Smoking reduces nasopharyngeal cancer survival

Both current and former smoking have a significant impact on the prognosis of patients with nasopharyngeal carcinoma, Chinese researchers caution.

26 Nov 2013

Transgene welcomes SillaJen’s intention to acquire Jennerex

Transgene SA (Paris:TNG) said today that it welcomed the announcement by SillaJen, Inc. of its intention to acquire Jennerex, Inc. and has consequently given its consent to the definitive merger agreement.

26 Nov 2013

SillaJen executes definitive merger agreement to acquire Jennerex

SillaJen, Inc., a privately-held biotherapeutics and contract research company focused on the development of targeted biological products for cancer, announced today that it had executed a definitive merger agreement to acquire San Francisco-based Jennerex, Inc.

26 Nov 2013

UV radiation: A central factor behind Queensland’s record rates of Merkel cell carcinoma

Queensland has at least double the rates of the world’s deadliest skin cancer on record – yet much of the state are unaware the rare cancer even exists.

25 Nov 2013

Radiation therapy now available via latest version of ACR ppropriateness Criteria

New and updated evidence-based guidelines to help health care providers choose the most appropriate medical imaging exam or radiation therapy for a patient's clinical condition are now available via the latest version of the American College of Radiology (ACR) Appropriateness Criteria.

25 Nov 2013

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.

23 Nov 2013

Smoking influences survival of nasopharyngeal carcinoma patients

Survivors of nasopharyngeal carcinoma who are former or current smokers are more likely to have their disease progress, relapse, or spread, and are more likely to die of their disease, compared with survivors of nasopharyngeal carcinoma who have never smoked, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

21 Nov 2013

First patients enrolled in EF-21 Study of NovoTTF Therapy for brain metastases from NSCLC cancer

Novocure announced today that the first patients have enrolled in the EF-21 Study, a prospective randomized clinical study of NovoTTF Therapy for patients with brain metastases from non-small cell lung carcinoma cancer. NovoTTF Therapy is an anti-mitotic treatment delivered continuously throughout the day by the NovoTTF-100A System.

20 Nov 2013

Vismodegib drug does not offer added benefits for patients with BCC

The drug vismodegib (trade name: Erivedge) is approved for the treatment of patients with two forms of basal cell carcinoma: symptomatic metastatic BCC and locally advanced BCC inappropriate for surgery or radiotherapy.

19 Nov 2013

New hope for patients whose melanoma has metastasised to the brain

New data show that in patients whose melanoma (BRAF V600 mutation-positive) has spread (metastasised) to the brain, Zelboraf (vemurafenib) extends life expectancy by over six months compared to chemotherapy.1 These results are welcome news for patients suffering from metastatic melanoma, as up to half of these patients are diagnosed with brain metastases with many given less than six months to live.1

18 Nov 2013

Aligned approach to advanced bladder cancer treatment very much needed, study says

New study, involving eight Italian research centres, concluded that an aligned approach to the treatment of advanced bladder cancer is much needed, while confirming previously published results on survival estimates of associated salvage therapies.

18 Nov 2013

ESBC joins with Athena Breast Health Network to advance personalized breast cancer risk assessment

Edith Sanford Breast Cancer (ESBC), part of the Sanford Health system based in Sioux Falls, SD, today announced it is partnering with the Athena Breast Health Network, a University of California program, to advance the use of a personalized breast cancer risk assessment.

16 Nov 2013

Carcinoma News and Research

Further Reading

Nanostring Technologies announces nationwide availability of Prosigna Breast Cancer Assay in 2014

Genetic deficiency in males can trigger hepatocellular carcinoma, type 2 diabetes

Study helps explain why survival gap persists for African-Americans with head and neck cancer

Increased levels of protein HSET linked with worse breast cancer outcomes in African-Americans

Study: Ethnic groups with high prevalence of diabetes have high hepatocellular carcinoma rates

MassBiologics gets FDA orphan drug designation for MBL-HCV1 antibody

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

LabCorp's HCV GenoSure NS3/4 test now available for Q80K polymorphism screening

Smoking reduces nasopharyngeal cancer survival

Transgene welcomes SillaJen’s intention to acquire Jennerex

SillaJen executes definitive merger agreement to acquire Jennerex

UV radiation: A central factor behind Queensland’s record rates of Merkel cell carcinoma

Radiation therapy now available via latest version of ACR ppropriateness Criteria

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Smoking influences survival of nasopharyngeal carcinoma patients

First patients enrolled in EF-21 Study of NovoTTF Therapy for brain metastases from NSCLC cancer

Vismodegib drug does not offer added benefits for patients with BCC

New hope for patients whose melanoma has metastasised to the brain

Aligned approach to advanced bladder cancer treatment very much needed, study says

ESBC joins with Athena Breast Health Network to advance personalized breast cancer risk assessment

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News